Navigation Links
Sinovac Completes Construction of H1N1 Virus Seed Bank

Production of Seasonal Influenza Vaccine Is Nearly Completed

BEIJING, June 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it has completed construction of the H1N1 virus seed bank necessary to produce a virus antigen.

Sinovac received the seed virus from the US Center for Disease Control (CDC) on June 8, 2009 and started the H1N1 vaccine production on the same day. Sinovac expects to complete production of the first batch and initiate clinical trials of an H1N1 vaccine by the end of July 2009.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "On June 11, 2009, the World Health Organization declared the H1N1 virus a pandemic influenza outbreak. Having completed the construction of our virus seed bank, our H1N1 vaccine production remains on track and we look forward to initiating clinical trials by the end of next month. Sinovac's rapid response to the newly emerged disease outbreak demonstrates the Company's resources and capabilities for vaccine production and highlights our commitment to protect the public from virus transmission through the timely supply of vaccines."

Sinovac's production of Anflu for the 2009/2010 Northern Hemisphere influenza season is nearly completed. The production of H1N1 vaccine will not affect its production and launch of the seasonal flu vaccine for this coming flu season.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Helen G. Yang
    Sinovac Biotech Ltd.
    Tel:  +86-10-8289-0088 x9871
    Fax:  +86-10-6296-6910

    Amy Glynn/Sara Pellegrino
    The Ruth Group
    Tel:  +1-646-536-7023/7002

    Janine McCargo
    The Ruth Group
    Tel:  656-536-7033

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
2. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
3. Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
4. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
5. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
6. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
7. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
8. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
9. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
10. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
11. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
Post Your Comments:
(Date:10/12/2015)... Carolina (PRWEB) , ... October 12, 2015 , ... Spirax ... announce the release of the CSM-C 600 compact clean steam generator . ... steam that meets the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C ...
(Date:10/12/2015)... , 12 de octubre de 2015 ... (D-CA) llegó a un récord en el congreso con ... anual de la International Plasma Awareness Week (IPAW), que ... IPAW está patrocinada por la Plasma Protein Therapeutics ... para: , Aumentar la concienciación mundial ...
(Date:10/12/2015)... , Oct. 12, 2015 VolitionRx Limited ... completed clinical study of its NuQ ® blood-based test ... online issue of Clinical Epigenetics , the official journal ... in collaboration with Lund University, ... , MD, PhD, Professor of Surgery and Vice-Dean, Faculty of ...
(Date:10/10/2015)... -- Le 8 octobre, l,honorable Doris O. Matsui ... Congrès sa déclaration de soutien à la troisième ... plasma (IPAW), qui se tiendra du 11 au ... Protein Therapeutics Association (PPTA) et ses sociétés ... Sensibiliser l,opinion publique mondiale autour du don de ...
Breaking Biology Technology:
(Date:9/29/2015)... -- iDAvatars is excited to be named one of the first ... official announcement was recently made at an invite-only IBM ... San Francisco , where iDAvatars presented a demo of ... "It is both an honor and a privilege to ... market the cognitive power of IBM Watson in our product, ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. ... interface solutions, today announced that Lenovo has selected Synaptics ... sensor, FS4202, for its latest smartphone, the Vibe P1. ... access to unlock the device and provide swift access ... The feature-rich Natural ID FS4202 sensor solution utilizes ...
(Date:9/10/2015)... Report Details Emerging Biological ... and Revenue Prospects to Help You Stay Ahead ... new drug classes? Get the latest technological and ... market data and industry knowledge, benefitting your influence. ... and sales predictions. Visiongain,s new study reveals ...
Breaking Biology News(10 mins):